If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
148
results.
Updated on
15/07/2026 [07:22:00]
Absstract of: DE102024139461A1
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung eines In-vitro-Modells für eine neurologische Erkrankung des Menschen. Darüber hinaus betrifft die Erfindung das gemäß dem hierin offenbarten erfindungsgemäßen Verfahren hergestellte In-vitro-Modell. Außerdem betrifft die Erfindung die Verwendung des In-vitro-Modells der Erfindung bei Arzneimitteltests. Darüber hinaus betrifft die Erfindung Verfahren zum Testen der Wirksamkeit von Arzneimitteln bei der Vorbeugung, Verzögerung und Linderung einer neurologischen Erkrankung des Menschen.
Absstract of: WO2026134539A1
The present invention relates to a DNA aptamer specifically binding to an alpha-synuclein protein and uses thereof. Specifically, the present invention relates to a DNA aptamer selected from the group consisting of nucleotide sequences of SEQ ID NOS: 1 to 12 and binding specifically to an α-synuclein protein, and a composition for detecting an α-synuclein protein, a detection kit, a detection chip or a microarray, all comprising the aptamer as an active ingredient. In addition, the present invention relates to a method for detecting an α-synuclein protein, a method for providing information for diagnosing a degenerative brain disease, a composition for diagnosing a degenerative brain disease, and a pharmaceutical composition for preventing or treating a neurodegenerative disease, all using the DNA aptamer of the present invention.
Absstract of: WO2026134051A1
This plasmalogen detection method comprises: a sample preparation step for mixing a Schiff's reagent and a specimen containing a plasmalogen to obtain a sample; a reaction step for reacting the plasmalogen in the sample with the Schiff's reagent; and a contact step for bringing at least some of the sample reacted in the reaction step into contact with a stationary phase containing a silica gel.
Absstract of: WO2026132535A1
The invention relates to an in vitro method for the differential diagnosis and/or prognosis of the presence or absence of a central nervous system (CNS) inflammation, in a subject with one or more symptoms of an acute neurological syndrome, said diagnosis and/or prognosis comprising: i) a CNS infection or ii) a neurological disorder without a CNS infection, or iii) an exclusion of i) and ii). The invention further relates to an in vitro method for detecting proadrenomedullin (proADM) or fragment(s) thereof in a cerebrospinal fluid sample. The invention further relates to kits for carrying out the methods of the invention.
Absstract of: WO2026132195A1
The present invention concerns the field of diagnostics. In particular, it relates to a method for analyzing a protein analyte in a heparin-treated sample comprising or suspected to comprise said protein analyte, said method comprising the step of contacting said heparin-treated sample with spermidine prior to analyzing the said protein analyte in the said sample. Moreover, contemplated are a method for assessing a cardiovascular disease or disorder, a neurological disease or disorder, a metabolic disease or disorder or cancer as well as kits and reagent compositions comprising spermidine to be used in the said methods.
Absstract of: US20260177568A1
The present invention provides lateral flow assay devices and methods for detecting nicotinic acetylcholine receptor ligands in liquid samples. The device comprises a porous strip with multiple zones, including a sample deposition zone, a test visualization zone containing an immobilized nicotine conjugate, a control zone, and an absorbent zone. A recombinant acetylcholine receptor protein serves as a mobile agent, either pre-deposited on the strip or added to the sample. The recombinant protein comprises a ligand-binding domain of a nicotinic acetylcholine receptor conjugated to a visually-detectable reporter forming a receptor-reporter conjugate. When nicotinic acetylcholine receptor ligands are present in the sample, they competitively bind to the recombinant receptor protein, reducing binding to the immobilized nicotine conjugate and producing a visually detectable signal inversely proportional to ligand concentration. The invention provides rapid, simple, and field-deployable detection of receptor ligands in environmental samples, including cyanobacterial neurotoxins in surface waters, and biological samples for pharmacological and toxicological applications.
Absstract of: DE102024139033A1
Die Erfindung betrifft ein Peptid, umfassend eine Aminosäuresequenz X6X7X8X9X10X11X12gemäß SEQ ID NO: 1, oder dessen pharmakologisch akzeptable Salze, Derivate und/oder Konjugate, wobei X6ist G oder A, X7ist R oder A, X8ist R oder A, X9ist T oder A, X10ist R oder A, X11ist L oder A, X12ist C oder A, mit der Maßgabe, dass eine der Aminosäuren an Position X6, X7, X8, X9, X10, X11oder X12Alanin sein kann, wobei das Peptid eine Gesamtlänge im Bereich von 7 bis 30 Aminosäuren aufweist, und wobei ein Peptid bestehend aus der Aminosäuresequenz KRRPAKAWSGRRTRLCC gemäß SEQ ID NO: 2 ausgenommen ist. Die Erfindung betrifft ferner Arzneimittel umfassend ein Peptid gemäß SEQ ID NO: 1 sowie eine Verwendung zur Herstellung eines Arzneimittels.
Absstract of: WO2026136613A1
The present invention relates to methods for treating an ophthalmic condition in a defined patient in need of treatment thereof. The methods comprise inducing the activity of peroxisome proliferator–activated receptor gamma coactivator-1 alpha (PGC1α) in a defined patient that needs treatment of an ophthalmic condition. The defined patient in these methods has been previously identified as having reduced carboxylesterase 1 (CES1) activity, compared to normal activity levels of CES1.
Absstract of: US20260177566A1
The present invention comprises a method for determining the biological age of an animal, wherein the method comprises determining the level of at least one biomarker in said animal, and wherein the at least 1 biomarker is selected from the biomarkers as listed in Table 1.
Absstract of: US20260177555A1
0000 The present disclosure relates to a method of separating, purifying, detecting, measuring, or analyzing a sample using a liquid chromatography.
Absstract of: US20260177567A1
The present invention comprises a method for determining the biological age of an animal, wherein the method comprises determining the level of at least one biomarker in said animal, and wherein the at least 1 biomarker is selected from the biomarkers as listed in Table 1.
Absstract of: WO2026134722A1
The present invention relates to a PTEN oxidative inactivation inducer comprising 1,1-diethoxyethane as an active ingredient and use thereof. More specifically, the present invention relates to: a PTEN oxidative inactivation inducer comprising 1,1-diethoxyethane (1,1-DEE) as an active ingredient; and use thereof, for example, a pharmaceutical composition, a cosmetic composition, a food composition, or a feed composition, as a composition for preventing, treating or ameliorating diseases requiring the oxidative inactivation of PTEN, and a method for detecting PTEN redox state.
Absstract of: US20260177560A1
A process for determining an extent of a central nervous system (CNS) specific neurological condition in a subject including collecting a biological sample of biofluid from the subject and measuring a quantity of a first biomarker, or metabolite of or mRNA corresponding to, the first biomarker from the sample from a dried spot or through a microfluidic device. The biofluid is capillary blood or saliva, which affords ease of collection advantages that are attractive for field-, hospital-, and home-based environments. The process being useful in the diagnosis, care, and management of brain specific abnormal neurological conditions in general, and in particular, to traumatic brain injury (TBI) and (TBI-induced) Alzheimer's disease (AD) and Alexander disease, in which a GFAP mutation is implicated in white matter deterioration.
Absstract of: US20260176364A1
0000 The invention relates to compositions and methods for producing and using antibodies against the alpha7 nicotinic acetylcholine receptor.
Absstract of: US20260177546A1
The invention provides a method for predicting the susceptibility of a patient suffering from a cancer or a myeloid-mediated disease to immunotherapy. Furthermore, the invention provides a method for treating a patient suffering from a cancer or a myeloid-mediated disease with immunotherapy. In accordance with these embodiments, the inventive method includes assaying myeloid cells obtained from the patient prior to treatment for the expression of CXCR3. The invention also provides a genetically engineered myeloid cell (GEMy) in which the expression of CXCR3 is modulated (up- or down-regulated). The invention further provides a composition comprising the inventive GEMy and a pharmaceutically acceptable carrier. The invention also provides a method for treating a patient in need of immunotherapy comprising administering the inventive composition to a patient.
Absstract of: US20260177544A1
An object of the present invention is to provide a highly sensitive method for detecting a biomarker. The object can be achieved by a method for detecting a test substance in a specimen of the present invention, the method being (A) a sandwich method including: (1) bringing a specimen into contact with a magnetic particle on which a primary substance is immobilized and which has a particle diameter that does not cause interference with a wavelength for measurement with a laser, to form a primary substance-test substance complex of the primary substance and a test substance in the specimen; (2) bringing the primary substance-test substance complex into contact with a secondary substance, to form a primary substance-test substance-secondary substance complex of the primary substance-test substance complex and the secondary substance; and (3) detecting the primary substance-test substance-secondary substance complex on the magnetic particle with a laser; or (B) a competitive method including: (1) bringing a specimen and a secondary substance into contact with a magnetic particle on which a primary substance is immobilized and which has a particle diameter that does not cause interference with a wavelength for measurement with a laser, to form a primary substance-secondary substance complex of the primary substance and the secondary substance; and (2) detecting the primary substance-secondary substance complex on the magnetic particle with a laser.
Absstract of: US20260176315A1
Use of an interleukin 27 (IL-27) protein in preparation of a product for treating and/or delaying Alzheimer's disease (AD) is provided, belonging to the technical field of biomedicine. The IL-27 protein refers to a recombinant IL-27 protein targeting a therapeutic target IL-27, and is selected from the group consisting of a mouse-derived IL-27 protein and a human-derived IL-27 protein, as well as a mammalian IL-27 protein other than the mouse-derived IL-27 protein and the human-derived IL-27 protein. The recombinant IL-27 protein can effectively alleviate the AD caused by Aβ deposition, and can selectively bind to a target receptor, thereby ensuring an accuracy of test results. The protein receptor is highly expressed in the dentate gyrus region of hippocampus, and guarantees drug targeting to the greatest extent.
Absstract of: EP4763997A1
The present invention relates to biomarkers capable of diagnosing various brain and nervous system diseases, and a method of providing information for diagnosing brain and nervous system diseases using the same. According to the present invention, it is possible to diagnose, at an early stage, the onset of a brain and nervous system disease or the likelihood of developing the disease or diagnose the progress or prognosis of the disease or the therapeutic effect against the disease, by measuring the expression level of the biomarker protein of the present invention or a gene encoding the same in the aqueous humor of the eye.
Absstract of: EP4764499A1
0001 The present invention relates to a method of detection of glycated proteins, particularly gHSA, which comprises the steps of: i) providing anthracene boronic acid methacrylate (ABAM): 10-N-methyl-N-(o-boronobenzyl)aminomethyl-anthracene-9-methyl methacrylate; ii) preparing a solution of ABAM in a biocompatible buffer with pH in the range of from 6.5 to 8.5 or in in vitro blood plasma sample of a healthy subject; iii) measuring initial fluorescence intensity of ABAM solution from step ii) at the wavelength of from 410 to 520 nm; iv) in vitro mixing of a known amount of ABAM solution from step ii) with a known amount of biological sample; v) measuring fluorescence intensity of the mixture from step iv) at the wavelength of from 410 to 520 nm; vi) determining the fluorescence intensity increases between the initial control fluorescence intensity measured in step iii) and the fluorescence intensity of the mixture of ABAM and biological sample measured in step v); vii) calculating the amount of glycated proteins in the biological sample. 0002 The present invention further relates to the use of this method in determination of the total concentrations of glycated proteins, particularly gHSA, in plasma samples and diagnostics for diabetes mellitus.
Absstract of: WO2025040574A1
Alzheimer's disease is strongly linked to biological aging and bioenergetic abnormalities. Systemic dysregulation of metabolism is a hallmark of the physiological decline of tissues with age. We aimed to explore untargeted metabolomic profiling of blood samples from amyloid-positive people to distinguish individuals who progressed to cognitive decline from those who remained cognitively intact despite having amyloid deposits in the brain. A minimal signature of 9 metabolites identified decliners and non-decliners of cognitive function in participants with an amyloid load. These findings are of clinical importance as they suggest that a metabolic fingerprint may help to predict patients who will develop cognitive decline. Due to the high prevalence of brain amyloid-positivity in older adults, identifying adults who will have cognitive decline will enable the development of personalized and early interventions. The present invention relates to an in vitro method for predicting cognitive decline in a subject comprising the step of determining the level of at least one metabolite selected in the group consisting of 3-hydroxybutyrate, acetone, triglyceride 48:3, glucose, citrate, succinate, methionine, serine, sphingomyelin d18:1/C26:0 in a biological sample obtained from the subject.
Absstract of: US2025123294A1
In one aspect, a method for screening an individual for head and neck cancer, which comprising: acquiring a saliva sample from the individual, analyzing the saliva sample to detect one or more of HPVs and at least one of a phenotypic biomarker, a regulatory biomarker, a microbiome-derived biomarker, and a metabolomic biomarker dysregulated due to HPV infection, wherein detection of both of the HPV and at least one of said biomarkers indicates the individual is at risk of head and neck cancer.
Absstract of: WO2020168254A1
A method of determining the potency of an immune cell is described. The method includes the steps of contacting an immune cell with an effective amount of a cell exosome and detecting the amount of a cytokine produced by the immune cell. Kits for assaying immune cell potency are also described. Potency assays are important for satisfying the FDA requirements for new biological agents, such as immunotherapeutic cells. Methods of using potent immune cells as an immunotherapeutic treatment are described.
Absstract of: CN122259816A
本发明涉及一种用于脑类器官药物测试的实时监测方法和系统，包括如下步骤：S1、进行脑类器官的制备与预培养；S2、微电极阵列芯片与反应微室的准备：将芯片安装于反应微室中，所述反应微室中央设计花瓣式流体槽结构，中心为样本腔体，外围的花瓣槽道与入口和出口流道相连；S3、脑类器官的装载与固定：在下层微电极阵列电极中心放置脑类器官后放置上层微电极阵列芯片，使脑类器官被夹持在上下电极之间，保证接触充分但不造成压伤；S4、药物灌注与电生理实时监测：将药物沿流道进入花瓣式流体槽并扩散至反应腔体，实时记录脑类器官电信号变化；S5、进行系统清洗与复用。
Absstract of: CN122256501A
0001 本发明涉及生物医药领域，具体涉及偏头痛诊断的生物标志物、试剂盒及其应用。本发明所述的偏头痛疾病相关的生物标志物包括COL4A2，同时还包括MMP‑14、LCAT、ADAMTS13和CPXM2中的任意一种或多种的组合。本发明基于临床健康对照和偏头痛患者的蛋白质组学数据，应用生信分析和机器学习等方法，深入挖掘对偏头痛疾病诊断最有预警价值的蛋白质组合，并在扩大样本的临床队列中进行验证，为新发现的生物标志物的临床转化提供良好前景，同时也为后续机制研究奠定基础。
Nº publicación: CN122255284A 23/06/2026
Applicant:
北京大学
Absstract of: CN122255284A
本发明涉及生物技术领域，具体的，本发明公开了一种酪氨酸碘化修饰PP2A蛋白的单克隆抗体、制备方法及应用。本发明通过制备酪氨酸碘化修饰的PP2A蛋白抗原肽，免疫兔制备单克隆抗体，并利用噬菌体展示技术淘选、表达载体扩增和ELISA筛选，最终获得一株能有效识别靶标的单克隆抗体R004。该抗体在免疫组织化学、细胞免疫荧光和蛋白免疫印迹中均表现出良好的灵敏度和特异性。本发明筛选得到的单克隆抗体可以用于PP2A蛋白催化亚基307位酪氨酸碘化修饰的检测中，为肿瘤诊断、抗肿瘤和神经疾病药物的研发提供支持。
BOPI
Electronic site
